StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Bio-Path Trading Down 13.6 %

Shares of Bio-Path stock opened at $0.16 on Monday. The firm has a 50-day simple moving average of $0.16 and a two-hundred day simple moving average of $0.59. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $4.55.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.